Intracellular pharmacokinetics of telithromycin, a ketolide antibiotic, in alveolar macrophages

被引:8
|
作者
Togami, Kohei [1 ]
Chono, Sumio [1 ]
Seki, Toshinobu [1 ,2 ]
Morimoto, Kazuhiro [1 ]
机构
[1] Hokkaido Pharmaceut Univ, Grad Sch Pharmaceut Sci, Dept Pharmaceut, Otaru, Hokkaido 0470264, Japan
[2] Josai Univ, Fac Pharmaceut Sci, Sakado, Saitama 35002, Japan
基金
日本学术振兴会;
关键词
acidic organelle; active transport; alveolar macrophages; intracellular pharmacokinetics; telithromycin; IN-VITRO ACTIVITY; EPITHELIAL LINING FLUID; STAPHYLOCOCCUS-AUREUS; HMR; 3647; MYCOBACTERIUM-TUBERCULOSIS; SUBCELLULAR-LOCALIZATION; ACCUMULATION; CLARITHROMYCIN; AZITHROMYCIN; PNEUMONIAE;
D O I
10.1211/jpp.62.01.0007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objectives Telithromycin, a ketolide antibiotic, has an antibacterial range that covers intracellular parasitic pathogens that survive or multiply intracellularly in alveolar macrophages. The intracellular pharmacokinetics of TEL in alveolar macrophages was evaluated in vitro. Methods Telithromycin (50 mu M) was applied to NR8383 as cultured alveolar macrophages, followed by incubation at 37 degrees C or 4 degrees C. After incubation, the amount of telithromycin in cells was determined. Key findings Telithromycin exhibited high accumulation in NR8383 and its intracellular accumulation was temperature dependent. Also, telithromycin distributed to the organelles and cytosol in NR8383 and, in particular, it accumulated in the acidic organelle compartments. Conclusions This study suggests that the high accumulation of telithromycin in NR8383 is due to its high influx via active transport systems and trapping in acidic organelles, such as lysosomes. Moreover, this study provides important information for optimizing the treatment of respiratory intracellular parasitic infections based on the intracellular pharmacokinetics of antibiotics and parasitic sites.
引用
收藏
页码:71 / 75
页数:5
相关论文
共 50 条
  • [1] Telithromycin -: Ketek® -: Levviax® -: Ketolide antibiotic
    不详
    DRUGS OF THE FUTURE, 2001, 26 (06) : 616 - 624
  • [2] Clinical Pharmacokinetics of Telithromycin, the First Ketolide Antibacterial
    Jun Shi
    Guy Montay
    Vijay O. Bhargava
    Clinical Pharmacokinetics, 2005, 44 : 915 - 934
  • [3] Clinical pharmacokinetics of telithromycin, the first ketolide antibacterial
    Shi, J
    Montay, G
    Bhargava, VO
    CLINICAL PHARMACOKINETICS, 2005, 44 (09) : 915 - 934
  • [4] Telithromycin (HMR 3647): The first ketolide antibiotic
    Xiong, YQ
    Le, TP
    DRUGS OF TODAY, 2001, 37 (09) : 617 - 628
  • [5] Pharmacokinetics and safety of the ketolide telithromycin in patients with renal impairment
    Shi, J
    Montay, G
    Chapel, S
    Hardy, P
    Barrett, JS
    Sack, M
    Marbury, T
    Swan, SK
    Vargas, R
    Leclerc, V
    Leroy, B
    Bhargava, VO
    JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 44 (03): : 234 - 244
  • [6] Telithromycin -: HMR-3647 -: Ketek® -: Ketolide antibiotic
    不详
    DRUGS OF THE FUTURE, 2000, 25 (06) : 655 - 660
  • [7] Telithromycin: A ketolide antibiotic for treatment of respiratory tract infections
    Lonks, JR
    Goldmann, DA
    CLINICAL INFECTIOUS DISEASES, 2005, 40 (11) : 1657 - 1664
  • [8] Intrapulmonary pharmacokinetics of telithromycin, a new ketolide, in healthy Japanese volunteers
    Kadota, JI
    Ishimatsu, Y
    Iwashita, T
    Matsubara, Y
    Tomono, K
    Tateno, M
    Ishihara, R
    Muller-Serieys, C
    Kohno, S
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (03) : 917 - 921
  • [9] Telithromycin: The first ketolide antimicrobial
    Nguyen, M
    Chung, EP
    CLINICAL THERAPEUTICS, 2005, 27 (08) : 1144 - 1163
  • [10] Pharmacokinetics of the ketolide telithromycin after single and repeated doses in patients with hepatic impairment
    Cantalloube, C
    Bhargava, V
    Sultan, E
    Vacheron, F
    Batista, I
    Montay, G
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2003, 22 (02) : 112 - 121